Evaxion A EVAX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Evaxion A (EVAX) is a healthcare company listed in the US with a market value of about $25M. In the twelve months to June 30, 2026 it had revenue of $7M and net income of -$9M, a net margin of -115.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -204%.
About Evaxion A
Evaxion A is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 8 years in our data.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7M | $8M | $3M | $73000 | $0 | — | — | — | — |
| Net income | -$9M | -$8M | -$11M | -$22M | -$23M | -$25M | -$15M | -$11M | -$6M |
| Free cash flow | -$7M | -$7M | -$13M | -$18M | -$26M | -$23M | -$13M | -$7M | -$2M |
| EPS (diluted) | $-1.04 | $-0.84 | $-1.15 | $-2.40 | $-2.51 | $-2.66 | $-1.63 | $-1.21 | $-0.60 |
| Net margin | -115.5% | -102.4% | -316.0% | -30308.2% | — | — | — | — | — |
| ROIC | — | -36.6% | -210.4% | -546.9% | -150.0% | -76.3% | -213.3% | -108.1% | -65.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $12.25, 347% above the current price; targets range from $9.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Evaxion A pay a dividend?
Not currently.
Is Evaxion A a good stock to buy?
We do not give buy or sell advice. Evaxion A scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.